Screening for Lynch Syndrome by Immunohistochemistry, BRAF Mutations Analysis, and MLH1 Promoter Methylation Analysis for Patients in Ontario with Colorectal or Endometrial Cancers
Research Question(s)
- For patients with CRC or EC, what is the evidence for using IHC testing to identify a) tumours that are MSI-H and b) tumours that are LS?
- How does IHC testing compare with MSI testing for identifying the MMR deficiencies characterizing LS in CRC tumours and endometrial tumours?
- For tumours that show abnormal MLH1 protein expression by IHC:
- How effective is BRAF V600E testing at differentiating between sporadic versus LS-associated CRC?
- How effective is MLH1 promoter methylation testing at differentiating between sporadic versus LS-associated CRC and EC?
- How effective is a combination of BRAF V600E testing and MLH1 promoter methylation testing at differentiating between sporadic versus LS-associated CRC and EC?
Modality:
Pathology and Laboratory Testing
PEBC:
PEBC
Guideline Identifier:
MOAC 3
Cancer Continuum:
Screening
Type of Content:
Authors:
A. Pollett
J. Brown
M. Aronson
B. Clark
N. Baxter
E. Tomiak
Molecular Oncology Advisory Committee
Universal Date:
2015-09-28 00:00:00